These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33587964)

  • 1. The current status of drug-coated devices in lower extremity peripheral artery disease interventions.
    Amlani V; Falkenberg M; Nordanstig J
    Prog Cardiovasc Dis; 2021; 65():23-28. PubMed ID: 33587964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mortality in patients undergoing revascularization with paclitaxel eluting devices for infrainguinal peripheral artery disease: Insights from a network meta-analysis of randomized trials.
    Kuno T; Ueyama H; Mikami T; Takagi H; Numasawa Y; Anzai H; Bangalore S
    Catheter Cardiovasc Interv; 2020 Oct; 96(4):E467-E478. PubMed ID: 32691953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Femoral-popliteal peripheral artery disease: From symptom presentation to management and treatment controversies.
    Krawisz AK; Raja A; Secemsky EA
    Prog Cardiovasc Dis; 2021; 65():15-22. PubMed ID: 33592208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ISAR-PEBIS (Paclitaxel-Eluting Balloon Versus Conventional Balloon Angioplasty for In-Stent Restenosis of Superficial Femoral Artery): A Randomized Trial.
    Ott I; Cassese S; Groha P; Steppich B; Voll F; Hadamitzky M; Ibrahim T; Kufner S; Dewitz K; Wittmann T; Kasel AM; Laugwitz KL; Schunkert H; Kastrati A; Fusaro M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28743787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
    Kinstner CM; Lammer J; Willfort-Ehringer A; Matzek W; Gschwandtner M; Javor D; Funovics M; Schoder M; Koppensteiner R; Loewe C; Ristl R; Wolf F
    JACC Cardiovasc Interv; 2016 Jul; 9(13):1386-92. PubMed ID: 27388828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Treatment of In-Stent Restenosis in the Superficial Femoral and Popliteal Arteries: The COPA CABANA Trial.
    Tepe G; Schroeder H; Albrecht T; Reimer P; Diehm N; Baeriswyl JL; Brechtel K; Speck U; Zeller T
    J Endovasc Ther; 2020 Apr; 27(2):276-286. PubMed ID: 32096451
    [No Abstract]   [Full Text] [Related]  

  • 7. The effectiveness of the paclitaxel-coated Luminor® balloon catheter versus an uncoated balloon catheter in superficial femoral and popliteal arteries in preventing vessel restenosis or reocclusion: study protocol for a randomized controlled trial.
    Teichgräber U; Aschenbach R; Scheinert D; Zeller T; Brechtel K; Thieme M; Blessing E; Treitl M; Lichtenberg M; von Flotow P; Vogel B; Werk M; Riambau V; Wienke A; Lehmann T; Sixt S
    Trials; 2016 Oct; 17(1):528. PubMed ID: 27793175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel-coated peripheral artery devices are not associated with increased mortality.
    Kumins NH; King AH; Ambani RN; Thomas JP; Bose S; Shishehbor MH; Li J; Wong VL; Harth KC; Cho JS; Kashyap VS
    J Vasc Surg; 2020 Sep; 72(3):968-976. PubMed ID: 31917036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of treatment with paclitaxel-coated devices for peripheral arterial disease.
    Kim TI; Kiwan G; Mohamedali A; Zhang Y; Mena-Hurtado C; Mojibian H; Guzman RJ; Ochoa Chaar CI
    J Vasc Surg; 2021 Mar; 73(3):911-917. PubMed ID: 33038480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long Term Outcomes After Revascularisations Below the Knee with Paclitaxel Coated Devices: A Propensity Score Matched Cohort Analysis.
    Heidemann F; Peters F; Kuchenbecker J; Kreutzburg T; Sedrakyan A; Marschall U; L'Hoest H; Debus ES; Behrendt CA
    Eur J Vasc Endovasc Surg; 2020 Oct; 60(4):549-558. PubMed ID: 32807674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-eluting balloon catheters for lower limb peripheral arterial disease: the evidence to date.
    Barkat M; Torella F; Antoniou GA
    Vasc Health Risk Manag; 2016; 12():199-208. PubMed ID: 27274265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease.
    Ouriel K; Adelman MA; Rosenfield K; Scheinert D; Brodmann M; Peña C; Geraghty P; Lee A; White R; Clair DG
    JACC Cardiovasc Interv; 2019 Dec; 12(24):2515-2524. PubMed ID: 31575518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary Patency of Long-Segment Femoropopliteal Artery Lesions in Patients with Peripheral Arterial Occlusive Disease Treated with Paclitaxel-Eluting Technology.
    Phair J; Carnevale M; Lipsitz EC; Shariff S; Scher L; Garg K
    Ann Vasc Surg; 2020 Jul; 66():595-600. PubMed ID: 31863948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mortality After Paclitaxel-Coated Device Use in Patients With Chronic Limb-Threatening Ischemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Dinh K; Gomes ML; Thomas SD; Paravastu SCV; Holden A; Schneider PA; Varcoe RL
    J Endovasc Ther; 2020 Apr; 27(2):175-185. PubMed ID: 32066315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease.
    Mehrotra S; Paramasivam G; Mishra S
    Curr Cardiol Rep; 2017 Feb; 19(2):10. PubMed ID: 28185166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 12-Month Results From the First-in-Human Randomized Study of the Ranger Paclitaxel-Coated Balloon for Femoropopliteal Treatment.
    Steiner S; Willfort-Ehringer A; Sievert H; Geist V; Lichtenberg M; Del Giudice C; Sauguet A; Diaz-Cartelle J; Marx C; Ströbel A; Schult I; Scheinert D;
    JACC Cardiovasc Interv; 2018 May; 11(10):934-941. PubMed ID: 29730375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel exposure and long-term mortality of patients treated with the Zilver PTX drug-eluting stent.
    Stern JR; Tran K; Chandra V; Harris EJ; Lee JT
    Vascular; 2021 Aug; 29(4):567-573. PubMed ID: 33054678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Safety of Paclitaxel-Coated Devices for Patients with Peripheral Artery Disease.
    Krawisz AK; Secemsky EA
    Curr Cardiol Rep; 2021 Mar; 23(5):48. PubMed ID: 33738616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-stent restenosis management: the best is yet to come.
    van den Berg JC
    J Cardiovasc Surg (Torino); 2017 Aug; 58(4):508-517. PubMed ID: 28322039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 12-month primary patency rates of contemporary endovascular device therapy for femoro-popliteal occlusive disease in 6,024 patients: beyond balloon angioplasty.
    Marmagkiolis K; Hakeem A; Choksi N; Al-Hawwas M; Edupuganti MM; Leesar MA; Cilingiroglu M
    Catheter Cardiovasc Interv; 2014 Oct; 84(4):555-64. PubMed ID: 24740749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.